Lineage Cell Therapeutics, Inc. Quarterly Lessee, Operating Lease, Liability, to be Paid, Year One in USD for Q2 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Summary
Lineage Cell Therapeutics, Inc. quarterly Lessee, Operating Lease, Liability, to be Paid, Year One history and growth rate for Q2 2022.
  • Lineage Cell Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid, Year One for the quarter ending June 30, 2022 was $531K.
Lessee, Operating Lease, Liability, to be Paid, Year One, Quarterly (USD)
Period Value YoY Chg Change % Date Report Filed
Q2 2022 $531K Jun 30, 2022 10-Q 2022-08-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.